States’ Rights: Marijuana Laws under the New Administration – A06

Hot Topics Track
Medical Marijuana Committee

Seminar Sponsored by:

Session A: 9:00 a.m – 10:30 a.m.

What does the new administration mean for medical marijuana in Connecticut? Candidate Trump indicated that, if elected, his administration would likely not interfere with state-run medical marijuana programs, but he expressed ambivalence toward states’ rights when it comes to recreational marijuana laws. President Trump has telegraphed a similar position, though has provided no definitive pronouncement or taken action on these issues to date.

You will learn:

  • About the current landscape of the federal regulation of medical marijuana
  • About the likely legal impact of regulatory change for Connecticut producers, providers, patients, and their third party business partners
  • An overview of this rapidly evolving legal arena


April Arrasate, April & Associates, Farmington

Attorney Arrasate is a Connecticut and South Carolina licensed attorney and is of counsel in the state of Florida. She is also Founder and Chair of the Connecticut Bar Association’s Medical Marijuana Committee. In 2013, April assembled a winning team and application to win one of four licenses to cultivate cannabis in the highly regulated state of Connecticut. As COO, she brought that license from permit to production in less than six months and continued to run the facility to full production of a robust product line serving the state dispensaries. She has recently formed April & Associates, harnessing her legal, pharmaceutical and cannabis industry contacts and experience to pursue national and international business development opportunities in cannabinoid medicine, research and drug policy initiatives.

Prior to her legal and entrepreneurial career, April worked in the biotech arena. She has worked in the field of pharmaceutical synthesis with Genzyme and with Harvard Medical School’s Channing Laboratory. At Harvard, April worked in antigen synthesis to create a novel pharmaceutical that was presented and ultimately procured by drug manufacturer Eli Lilly.

In 2011, April’s Mother lost a two year struggle with breast cancer. As her caregiver, the illness and ultimate loss transformed April into a passionate and experienced patient advocate. Since then, she has combined her biochemical and legal experience to pursue the use of medical cannabis as a means of improving quality of life for patients and exploring the potential curative properties of cannabis as a cancer treatment. This drive coupled with her entrepreneurial success in several medical marijuana approved states has led to her position on the national and international frontlines of cannabis issues.


Steph Sherer, Executive Director, Americans for Safe Access

Attorney Sherer is founder and Executive Director of Americans for Safe Access (ASA), Director of Innovations of the International Cannabis and Cannabinoid Institute (ICCI), and founding member of the International Medical Cannabis Patients Coalition (IMCPC). ASA is the largest national member-based organization of patients, medical professionals, scientists, and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. Steph has become the foremost international leader and expert on medical cannabis patient advocacy and, alongside the American Herbal Products Association (AHPA), has created the first industry standards in the areas of Distribution, Cultivation, Analytics, and Manufacturing, Packaging, and Labeling.


Lila McKinley, Department of Consumer Protection, Hartford

Attorney McKinley is a Staff Attorney with the Connecticut Department of Consumer Protection.  Prior to joining the Department of Consumer Protection, Lila was an attorney in the private sector with a large regional law firm specializing in Professional Liability. Lila received her law degree from the University of Connecticut School of Law and her undergraduate degree from the University of Connecticut.





CLE Credit: 1.5 Hours